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Abstract
The clinical and microbiological characteristics of 103 patients
with cultures positive for non-Aspergillus moulds in the period
2000 to 2008 were described. Among these patients, 27 had
proven or probable invasive infections caused by Fusarium
(n = 12), Paecilomyces (n = 7), Zygomycetes (n = 5) and Scedo-
psorium species (n = 3). The incidence of invasive infections
caused by these moulds has not increased during the study per-
iod. Lung was the most common infection site and disseminated
disease was observed in three leukaemic patients. The overall
mortality rate was 40.7%, and was highest in cases zygomycosis.
Antifungal susceptibility varied considerably among species.
Amphotericin B and posaconazole demonstrated greatest activity
against these moulds.
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Invasive mould infections (IMIs) have emerged as a signiﬁcant
cause of infectious mortality in immunocompromised
patients [1]. Although invasive aspergillosis (IA) represents
the most common opportunistic mould infection, less com-
monly encountered moulds, such as Zygomycetes, Fusarium,
Paecilomyces and Scedosporium species, have increasingly been
reported to cause IMIs [2–5]. Moreover, infections caused
by these organisms are associated with a substantially worse
outcome than IA [1], which is most likely attributed both to
the signiﬁcant immunodeﬁcient state of these patients and
the innate resistance of these organisms to antifungal agents
[4,6–8].
Because of the rarity of non-Aspergillus invasive infections,
there is limited literature on the clinical characteristics of
these mycoses [1,5,9]. Furthermore, reports on the drug
susceptibility of these organisms are scarce [6–8,10].
In the present study, patients with cultures positive for
Fusarium, Zygomycetes, Paecilomyces and Scedosporium species
in the period 2000 to 2008 at the National Taiwan Univer-
sity Hospital were identiﬁed. Invasive mould infections were
deﬁned in accordance with the EORTC/MSG criteria [11].
The use of steroids was deﬁned as usage within 30 days
prior to obtaining the positive culture. Infection with the
involvement of two or more noncontiguous organ sites was
considered as disseminated disease. The outcome of the
patients was deﬁned as their status at 12 weeks after diagno-
sis. The isolates were identiﬁed to the species level by
sequence comparison analysis of the internal transcribed
spacer (ITS) regions using primers ITS1 and ITS4 as previ-
ously described [12]. For Fusarium species, sequence analysis
of the translation elongation factor 1 alpha (EF1a) region
was also performed with primers EF1 and EF2 [13]. MICs
were determined by the broth microdilution method [14].
Among the 141 positive cultures obtained from 103
patients, 27 cases (26.2%) met the criteria for proven or
probable IMI. The aetiologic pathogens were Fusarium spe-
cies in 12 (44.4%) patients, Paecilomyces species in seven
(25.9%), Zygomycetes in ﬁve (18.5%) and Scedopsorium spe-
cies in three (11.1%) (Table 1). The annual incidence of IMIs
caused by these ranged from 0.04 per 1000 admissions in
2006 to 0.31 per 1000 admissions in 2000, and was 0.17 per
1000 admissions in both 2007 and 2008. The reason we did
not observe a similar trend of increased incidence of infec-
tions, as has been reported previously [3–5], remains
unknown. The limited use of broad-spectrum antifungal agents
for prophylaxis in the hospital might partly explain this phe-
nomenon [3–5,15].
Predisposing factors were identiﬁed in 25 of the 27
patients and included haematological malignancies (48%),
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steroid use (10.40%), solid organ tumor (3.12%), haemato-
poietic stem cell (1.4%) or solid organ transplantation (12%),
AIDS (2.8%), diabetes mellitus (2.8%) and myelodysplastic
syndrome (1.4%). The lung was the most common main
infection site (33%), followed by orbito-sinus-facial (18.5%),
skin and soft tissue (18.5%), blood (11.1%) and bile (7.4%).
Disseminated disease was observed in three leukaemic
patients who all presented with skin involvement.
A total of 21 patients received antifungal therapy and six
patients received surgical treatment. Overall, amphotericin B
(including liposomal amphotericin B) was the most frequently
administered agent (81.0%), followed by ﬂuconazole (52.4%),
voriconazole (33.3%), itraconazole (23.8%) and caspofungin
(9.5%).
Mortality at 12 weeks for all patients was 40.7%, and 76.9%
for patients with haematological malignancies. Mortality was
highest in patients with zygomycosis (four out of ﬁve patients
died; 80%), despite all ﬁve patients in this group receiving anti-
fungal therapy and three patients undergoing surgical treat-
ment. All four patients who died had acute leukaemia, and
one of them was an allogenic haematopoietic stem cell trans-
plantat recipient. Patients with fusariosis were associated with
the second highest mortality rate (41.7%), and all those who
died had underlying haematological disorders.
Fifty-eight clinical isolates were available for ITS sequence
analysis. The identiﬁed organisms include 29 Fusarium, 18
Paecilomyces, seven Zygomycetes and four Scedosporium spe-
cies. Among the isolates, 41 reported only to the genus level
by conventional methods were further identiﬁed to the spe-
cies level. Of note, six isolates initially reported as Paecilomy-
ces species by conventional methods were found to be
Penicillium species (three isolates), Aspergillus versicolor (one
isolate), different species of Paecilomyces (one isolate) and
mixed Paecilomyces and Penicillium infection (one isolate) by
sequence analysis. It has been reported that Paecilomyces and
Penicillium species are often misidentiﬁed as a result of their
similar reproductive structures [15].
The geometric means and ranges of the MICs for eight
antifungal agents are summarized in Table 2. Fusarium species
TABLE 1. Demographic characteristics of 27 patients with
proven and probable invasive unusual mould infections
Characteristic Fusarium Paecilomyces Zygomycetes Scedosporium
Number (%) of
patients
12 (44.4) 7 (25.9) 5 (18.5) 3 (11.1)
Age, median (range) 39.5 (0–79) 60 (9–82) 37 (23–81) 65.4 (48–78)
Male 6 (50) 4 (57) 3 (60) 3 (75)
Diagnosis
Acute leukaemia 5 2 4 0
Lymphoma 1 0 0 0
MDS 1 0 0 0
Solid tumour 1 1 0 1
AIDS 0 2 0 0
Diabetes mellitus 0 2 0 0
HSCT 0 0 1 0
Solid organ
transplant
1 0 1 1
Immunological risk factors
Steroid use 6 1 1 2
Neutropenia
< 500/lL
4 2 2 0
Lymphopenia
< 1500/lL
7 2 2 0
Site of infection
Lung 4 3 1 1
Skin, soft tissue 2 1 1 1
Blood 1 2 0 0
Sinus 2 1 2 0
Bile 1 0 0 1
Disseminated 2 0 1 0
Treatment
Antifungal therapy 9 4 5 3
Amphotericin B 9 3 3 2
Fluconazole 7 0 3 1
Voriconazole 4 3 0 0
Itraconazole 1 3 0 1
Caspofungin 1 0 1 0
Surgical treatmenta 1 2 3 0
Mortality 5 (41.7) 2 (28.6) 4 (80.0) 0 (0)
MDS, meylodysplastic syndrome; HSCT, haematopoietic stem cell transplant.
aSix patients received surgical treatment, including lung decortication (n = 2),
maxillectomy with eye extenteration (n = 1), eye evisceration (n = 1), arthro-
scopic surgery (n = 1) and functional sinus surgery (n = 1).
TABLE 2. In vitro susceptibility of non-Aspergillus mould species to eight antifungal agent
Species
Number
of
isolates
MICs (mg/L), geometric mean (range)
Amphotericin B Fluconazole Itraconazole Voriconazole Posoconazole Caspofungin Micafungin Anidulafungin
Fusarium solani 26 0.95 (0.5–2) >64 (>64) >16 (>16) 17.8 (4–>16) >16 (>16) >16 (>16) >16 (>16) >16 (>16)
Fusarium equiseti 2 1 (1) >64 (>64) 8 (2–>16) 4 (4) >16 (>16) >16 (>16) >16 (>16) >16 (>16)
Paecilomyces variotii 5 0.06 (0.03–0.25) >64 (>64) 0.015 (0.015) 6.96 (4–8) 0.03 (0.015–0.06) 4.59 (2–16) 0.06 (0.015–16) 0.060 (0.015–16)
Paecilomyces lilacinus 3 >16 (>16) 80.63 (64–>64) >16 (>16) 0.25 (0.25) 0.40 (0.25–0.5) >16 (>16) >16 (>16) >16 (>16)
Paecilomyces
spectabilis
2 0.04 (0.03–0.06) >64 (>64) 0.015 (0.015–0.015) 5.66 (4–8) 0.042 (0.03–0.06) 1 (0.5–2) 0.015 (0.015) 0.015 (0.015)
Paecilomyces sinensis 1 0.12 >64 0.015 16 0.12 0.25 0.015 0.015
Scedosporium
apiospermum
2 5.66 (1–>16) 45.25 (32–64) 0.71(0.5–1) 0.5 (0.5) 0.71 (0.5–1) 16 (16) 22.63 (16–>16) 22.63 (16–>16)
Scedosporium
proliﬁcans
1 >16 >64 >16 16 >16 >16 >16 >16
Absidia corymbifera 2 0.08 (0.06–0.12) >64 (>64) 0.35 (0.25–0.5) 22.6 (16–>16) 0.25 (0.25) 22.6 (16–>16) >16 (>16) 22.6 (16–>16)
Cunninghamella
bertholletiae
2 0.71 (0.5–1) >64 (>64) 4 (0.5–32) >16 (>16) 0.71 (0.5–1) >16 (>16) >16 (>16) >16 (>16)
Rhizopus oryzae 2 0.12 (0.06–0.25) >64 (>64) >16 (>16) 22.6 (16–>16) 5.7 (1–>16) >16 (>16) >16 (>16) >16 (>16)
Rhizopus
microsporus
1 0.25 >64 >16 1 >16 >16 >16 >16
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exhibited high MICs for azoles and echinocandins, whereas
100% of the isolates were inhibited by £2 mg/L of amphoter-
icin B. Paecilomyces isolates showed different susceptibility
patterns among species. Several drugs demonstrated good
in vitro activity against Paecilomyces variotii, whereas Paecilomy-
ces lilacinus isolates had high MICs for most agents except
for voriconazole and posaconazole. The susceptibility pat-
terns of the rare species Paecilomyces spectabilis and Paecil-
omyces sinensis were similar to that of P. variotii. For the
Zygomycetes, amphotericin B was the most active agent.
Finally, Scedosporium apiospermum was relatively susceptible
to the newer azoles, whereas S. proliﬁcans had high MICs for
all antifungal agents tested.
Although Zygomycetes were the most commonly identi-
ﬁed non-Aspergillus moulds recorded in other reports [1,3],
Fusarium species comprised the rare moulds that were most
frequently isolated in the present study. In addition, although
Fusarium oxysporum and Fusarium moniliforme were found by
multiple studies to be the most frequently isolated species
after Fusarium solani [3,6], we did not identify either of these
two species by sequence analysis. Instead, two isolates of
Fusarium equisetii were detected. Furthermore, Paecilomyces
infections constituted a signiﬁcant proportion of IMIs in
the present study (25.9%). The unique species distribution
observed in the present study could be due to geography
because most of the previous studies were conducted in
Europe and North America [1–5].
In conclusion, non-Aspergillus IMIs occurred predominantly
in immunocompromised patients. Patients with underlying
haematological disorders were associated with an increased
risk of disseminated disease and high mortality. Antifungal
susceptibility varied considerably among these species. This
emphasizes the importance of identifying infecting moulds to
the species level, which is seldom achieved in standard clini-
cal laboratories.
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